Retrospective analysis of vancomycin nephrotoxicity in elderly Chinese patients

Pharmacology

Volumn 95, Issue 5-6, 2015, Pages 279-284

  Liu, Yan ^a   Yin, You ^b   Liu, Xin Zhu ^a   Yao, Hui Juan ^a   Li, Li Xia ^a   Chen, Ji Hui ^a   Chen, Ting ^a   Lu, Xiao Tong ^a   Bu, Shu Hong ^a   Zhang, Jian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Nephrotoxicity; Risk; Trough levels; Vancomycin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; VANCOMYCIN; ANTIINFECTIVE AGENT;

AGED; ARTICLE; CHINESE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SHOCK; ACUTE KIDNEY INJURY; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; CHINA; MIDDLE AGED;

ACUTE KIDNEY INJURY; AGED; ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 84929671023     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000381783     Document Type: Article

References (36)

1. Fairbrother RW, Williams BL: Two new antibiotics; antibacterial activity of novobiocin and vancomycin. Lancet 1956; 271: 1177-1178
2. Stevens DL: The role of vancomycin in the treatment paradigm. Clin Infect Dis 2006; 42(suppl 1): S51-S57
3. Kullar R, Davis SL, Taylor TN, Kaye KS, Rybak MJ: Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy 2012; 32: 195-201
4. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC Jr, Craig WA, Billeter M, Dalovisio JR, Levine DP: Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Pharmacotherapy 2009; 29: 1275-1279
5. Wong-Beringer A, Joo J, Tse E, Beringer P: Vancomycin-Associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011; 37: 95-101
6. Mangin O, Urien S, Mainardi JL, Fagon JY, Faisy C: Vancomycin pharmacokinetic and pharmacodynamic models for critically ill patients with post-sternotomy mediastinitis. Clin Pharmacokinet 2014; 53: 849-861
7. Geraci JE, Heilman FR, Nichols DR, Wellman WE: Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis; preliminary report. Proc Staff Meet Mayo Clin 1958; 33: 172-181
8. Hanrahan TP, Harlow G, Hutchinson J, Dulhunty JM, Lipman J, Whitehouse T, Roberts JA: Vancomycin-Associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis. Crit Care Med 2014; 42: 2527-2536
9. Rostas SE, Kubiak DW, Calderwood MS: High-dose intravenous vancomycin therapy and the risk of nephrotoxicity. Clin Ther 2014; 36: 1098-1101
10. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D: Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844-850
11. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47-55
12. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ: Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63: 1121-1129
13. Perazella MA: Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol 2009; 4: 1275-1283
14. Guo X, Nzerue C: How to prevent, recognize, and treat drug-induced nephrotoxicity. Cleve Clin J Med 2002; 69: 289-290, 293-294, 296-297
15. Gurwitz JH, Avorn J, Ross-Degnan D, Lipsitz LA: Nonsteroidal anti-inflammatory drugassociated azotemia in the very old. JAMA 1990; 264: 471-475
16. Whelton A, Hamilton CW: Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991; 31: 588-598
17. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S: Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ 2013; 346: e8525
18. Hernández-Díaz S, García-Rodríguez LA: Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 2001; 110(suppl 3A): 20S-27S.
19. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A; Acute Kidney Injury Network: Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31
20. Kralovicová K, Spanik S, Halko J, Netriova J, Studena-Mrazova M, Novotny J, Grausova S, Koren P, Krupova I, Demitrovicova A, Kukuckova E, Krcmery V Jr: Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients?. J Chemother 1997; 9: 420-426
21. Zimmermann AE, Katona BG, Plaisance KI: Association of vancomycin serum concentrations with outcomes in patients with grampositive bacteremia. Pharmacotherapy 1995; 15: 85-91
22. Fanos V, Cataldi L: Renal transport of antibiotics and nephrotoxicity: a review. J Chemother 2001; 13: 461-472
23. Oktem F, Arslan MK, Ozguner F, et al: In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine. Toxicology 2005; 215: 227-233
24. Dieterich C, Puey A, Lin S, et al: Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates. Toxicol Sci 2009; 107: 258-269
25. Hong S, Valderrama E, Mattana J, et al: Vancomycin-induced acute granulomatous interstitial nephritis: therapeutic options. Am J Med Sci 2007; 334: 296-300
26. Downs NJ, Neihart RE, Dolezal JM, Hodges GR: Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 1989; 149: 1777-1781
27. Moellering RC Jr, Krogstad DJ, Greenblatt DJ: Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981; 94: 343-346
28. Cimino MA, Rotstein C, Slaughter RL, Emrich LJ: Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 1987; 83: 1091-1097
29. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH: Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679-687
30. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH: A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-Associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29: 1107-1115
31. Lodise TP, Lomaestro B, Graves J, Drusano GL: Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52: 1330-1336
32. McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A, Le J: Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr 2011; 158: 422-426
33. Cappelletty D, Jablonski A, Jung R: Risk factors for acute kidney injury in adult patients receiving vancomycin. Clin Drug Investig 2014; 34: 189-193
34. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A: High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-2144
35. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL: Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49: 507-514
36. Spapen HD, Janssen Van Doorn K, Diltoer M, Verbrugghe W, Jacobs R, Dobbeleir N, Honoré PM, Jorens PG: Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients. Ann Intensive Care 2011; 1: 26